1215071-23-0 Usage
Uses
Used in Organic Synthesis:
Tert-butyl (3,3-difluorocyclopentyl)carbamate serves as a reagent in organic synthesis, contributing to the creation of various chemical compounds and molecules. Its unique structure allows it to participate in a range of reactions, facilitating the synthesis of complex organic molecules.
Used in Pharmaceutical Research:
In the realm of pharmaceutical research, tert-butyl (3,3-difluorocyclopentyl)carbamate is utilized for its potential to contribute to the development of new drugs and molecular compounds. Its distinctive chemical characteristics make it a promising candidate for the design and synthesis of pharmaceutical agents.
Used in Drug Production:
Tert-butyl (3,3-difluorocyclopentyl)carbamate also functions as a building block in the production of various pharmaceutical drugs. Its incorporation into drug molecules can enhance their efficacy, selectivity, and other pharmacological properties, making it an important component in the development of novel therapeutic agents for diverse medical applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1215071-23-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,1,5,0,7 and 1 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1215071-23:
(9*1)+(8*2)+(7*1)+(6*5)+(5*0)+(4*7)+(3*1)+(2*2)+(1*3)=100
100 % 10 = 0
So 1215071-23-0 is a valid CAS Registry Number.
1215071-23-0Relevant academic research and scientific papers
SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
-
Paragraph 0422, (2016/05/02)
Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK
-
Page/Page column 94-95, (2010/12/29)
Disclosed are JAK inhibitors of formula (I) where G1, R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. Also disclosed are pharmaceutical compositions, kits and articles of manufacture which contain the compounds, methods and materials for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other diseases, disorders or conditions associated with JAK.
